Stock Chart

EWTX

$45.93 +0.24%
Score: 31.0 AVOID NEW MONEY
Pro
Screener
Vol: 0.68x (vs SPY: 0.9x | vs QQQ: 0.9x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Chart Pattern · as of Nov 13, 2026
Bull Pennant Bullish scenario quality 70/100
Setup invalidates on a close below $44.66 · pole +34% — no price target (measured-move targets failed our backtest for flags/pennants)
Historically breaks up 70% of the time (n=1,684). Measured-move targets failed our backtest — none shown.
Pattern detection is automated and probabilistic — a scenario map for levels, not a buy/sell signal. Rails, projected path and invalidation level are drawn on the chart below.
Technical Chart
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About EWTX - Edgewise Therapeutics, Inc. Common Stock

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are …

Key Statistics

Market Cap $5B
P/E Ratio 5.47

This EWTX stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track EWTX's price movements with trendlines, gamma walls, and key support/resistance levels.